Results 41 to 50 of about 691 (136)

Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs

Российский кардиологический журнал, 2019
Aim. To assess the possibility of azilsartan medoxomil to achieve target blood pressure (BP) (less than 130/80 mm Hg), to study angioprotective features and reduction of adipokines levels and inflammatory markers in patients with hypertension and ...
S. V. Nedogoda, E. V. Chumachek, V. V. Tsoma, A. S. Salasyuk, V. O. Smirnova, E. A. Popova   +5 more
doaj   +1 more source

COMBINATION OF AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE: IS IT POSSIBLE TO FIGHT SYSTEMIC HYPERTENSION AND OBESITY TOGETHER?

Российский кардиологический журнал, 2017
Arterial hypertension (AH) and obesity are the main risk factors of chronic noncommunicable diseases. Adipous tissue is not only a depot for energetic compounds, but is an active endocrine organ synthetizing biologically active substances that facilitate
Yu. A. Vasyuk, E. Yu. Shupenina, E. A. Nesterova, E. I. Golubkova, V. V. Nesvetov   +4 more
doaj   +1 more source

Azilsartan: Current Evidence and Perspectives in Management of Hypertension

International Journal of Hypertension, Volume 2019, Issue 1, 2019., 2019
Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP).
Akshyaya Pradhan, Ashish Tiwari, Rishi Sethi, Tomohiro Katsuya   +3 more
wiley   +1 more source

AZILSARTAN AS A POTENT ANTIHYPERTENSIVE DRUG WITH POSSIBLE PLEIOTROPIC CARDIOMETABOLIC EFFECTS: A REVIEW STUDY.

Frontiers in Pharmacology, 2016
Background: Hypertension related cardiovascular (CV) complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high
Georgiopoulos Georgios, Vasiliki Katsi, Dimitrios Oikonomou, Georgia Vamvakou, Evangelia Koutli, Aggeliki Laina, Constantinos Tsioufis, Petros Nihoyannopoulos, Petros Nihoyannopoulos, Dimitrios Tousoulis   +9 more
doaj   +1 more source

Metal‐Catalyzed Transformations of Carbon Dioxide Toward the Production of Commodity Chemicals

Advanced Synthesis &Catalysis, Volume 368, Issue 17, 1 September 2026.
This perspective highlights how transition‐metal catalysis can enable the synthesis of economically attractive CO2‐derived commodity chemicals. By transforming waste CO2 into acrylic acid, cyclic carbonates, and other valuable products, these strategies provide a practical route for simultaneous CO2 sequestration and valorization, helping to align ...
Chaodi Dai, Tu Anh Tran, Craig Stephen Day   +2 more
wiley   +1 more source

Systematic Review with Network Meta‐Analysis: Comparative Efficacy and Safety of Combination Therapy with Angiotensin II Receptor Blockers and Amlodipine in Asian Hypertensive Patients

International Journal of Hypertension, Volume 2019, Issue 1, 2019., 2019
Background. Hypertension (HTN) is the leading risk factor for cardiovascular mortality globally. The WHO estimates a 60% increase in Asian HTN patients between 2000 and 2025. Numerous studies have compared safety and efficacy between antihypertensive classes, but in‐class comparisons of angiotensin II receptor blockers (ARBs) in combination therapy (CT)
Dae Wook Lee, Mira Jung, Hye Won Wang, Zainah Khan, Philippe Pinton, Tomohiro Katsuya   +5 more
wiley   +1 more source

Evaluation of Characteristics and Ethnic Sensitivity for FDA‐Approved Drugs with Racial and Ethnic Differences in Pharmacokinetics, Safety, and Efficacy

The Journal of Clinical Pharmacology, Volume 65, Issue 11, Page 1381-1391, November 2025.
Abstract Racial and ethnic differences in drug disposition and response may have a significant impact on its risk‐benefit balance. Therefore, it is important to examine whether an investigational drug has characteristics that make the pharmacokinetics (PK), safety, and efficacy likely to be affected by intrinsic and extrinsic ethnic factors based on ...
Kei Fukuhara, Yusuke Tanetsugu, Shinsuke Wada, Chieko Muto, Norisuke Kawai   +4 more
wiley   +1 more source

FORMULATION AND IN VITRO EVALUATION OF AZILSARTAN MEDOXOMIL NANOSUSPENSION

International Journal of Pharmacy and Pharmaceutical Sciences, 2017
Objective: The objective of this study was to formulate and evaluate of the poorly soluble drug, azilsartan medoxomil into nanosuspension to increase the solubility and enhance the dissolution rate and then improve its bioavailability.Methods: Nanosuspension of azilsartan medoxomil was prepared using solvent-antisolvent precipitation method using PVP ...
Nizar Awish Jassem, Nawal Ayash Rajab
openaire   +2 more sources

Uptake and metabolization of four sartan drugs by eight different plants: Targeted and untargeted analyses by HPLC‐drift‐tube‐ion‐mobility quadrupole time‐of‐flight mass spectrometry

ELECTROPHORESIS, Volume 46, Issue 3-4, Page 135-142, February 2025.
Abstract In this study, we investigated the uptake and metabolization of four drugs (plus the associated prodrugs) from the sartan family by eight edible plants. Growing the plants hydroponically in a medium containing the respective drug, more than 40 phases I and II metabolites derived from the four sartan drugs could be tentatively identified.
Laura Zellner, Thomas Schiefer, Markus Himmelsbach, Franz Mlynek, Christian W. Klampfl   +4 more
wiley   +1 more source

Aerobic Exercise and Pharmacological Therapies for Skeletal Myopathy in Heart Failure: Similarities and Differences

Oxidative Medicine and Cellular Longevity, Volume 2016, Issue 1, 2016., 2016
Skeletal myopathy has been identified as a major comorbidity of heart failure (HF) affecting up to 20% of ambulatory patients leading to shortness of breath, early fatigue, and exercise intolerance. Neurohumoral blockade, through the inhibition of renin angiotensin aldosterone system (RAS) and β‐adrenergic receptor blockade (β‐blockers), is a mandatory
Aline V. Bacurau, Telma F. Cunha, Rodrigo W. Souza, Vanessa A. Voltarelli, Daniele Gabriel-Costa, Patricia C. Brum, Matthew C. Zimmerman   +6 more
wiley   +1 more source